{"id":39518,"date":"2026-08-31T09:26:00","date_gmt":"2026-08-31T13:26:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39518"},"modified":"2026-08-23T12:47:14","modified_gmt":"2026-08-23T16:47:14","slug":"why-well-catch-it-in-the-quarterly-review-is-how-companies-miss-nce-1-dates-every-year","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/why-well-catch-it-in-the-quarterly-review-is-how-companies-miss-nce-1-dates-every-year\/","title":{"rendered":"Why “We’ll Catch It in the Quarterly Review” Is How Companies Miss NCE-1 Dates Every Year"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

On September 9, 2026, Bristol-Myers Squibb’s five-year new chemical entity (NCE) exclusivity for Sotyktu (deucravacitinib) reaches its four-year mark. That date is the NCE-1 date: the first day a generic company can file an Abbreviated New Drug Application (ANDA) against Sotyktu with a Paragraph IV patent certification. Four patents currently protect the drug in the Orange Book [1]. Whoever files a substantially complete Paragraph IV ANDA on that single day, not the day before and not the day after, is positioned to win 180 days of generic market exclusivity once litigation and review conclude. Anyone who files a day late shares nothing.<\/p>\n\n\n\n

That is not an unusual situation. It is the normal operating condition of the generic drug industry, and it recurs on a predictable four-year lag behind every NCE approval. What is unusual is how many companies still manage a same-day-precision deadline through a quarterly-cadence process: a legal or regulatory affairs review that happens four times a year, roughly every 90 days, built for financial reporting and portfolio oversight rather than for a filing window measured in hours.<\/p>\n\n\n\n

This article uses documented cases (Aubagio, Vascepa, Cialis, Loestrin 24 Fe, and Provigil) to show why that mismatch is structural, not accidental, and to lay out an original taxonomy of the four places where quarterly governance cadence and day-precision regulatory deadlines diverge. It draws on FDA guidance, federal court decisions, SEC filings, and FDA’s own ANDA approval letters, along with DrugPatentWatch’s Orange Book and NCE-1 tracking data.<\/p>\n\n\n\n

What the NCE-1 Date Actually Requires<\/strong><\/h2>\n\n\n\n

The statutory basis for NCE-1 filing sits in section 505(j)(5)(F)(ii) of the Food, Drug, and Cosmetic Act, implemented at 21 C.F.R. \u00a7 314.108(b)(2) [2]. A new chemical entity gets five years of exclusivity during which FDA cannot accept an ANDA referencing it. The one exception: an ANDA filed with at least one Paragraph IV certification against an Orange Book patent can be accepted starting exactly four years after NDA approval. That four-year mark is what the industry calls the NCE-1 date. It is not a range. It is a single calendar day, calculated by adding four years to the NDA approval date [3].<\/p>\n\n\n\n

Being first to file a substantially complete ANDA with a Paragraph IV certification on that day, or being one of several companies who file complete applications on that same first day, determines who gets 180 days of shared first-filer exclusivity. Companies that file a day early are rejected as premature. Companies that file a day late compete in an already-crowded generic market with no exclusivity at all [4].<\/p>\n\n\n\n

Why Four Years Is Not a Guideline<\/strong><\/h3>\n\n\n\n

FDA has been explicit that this is a bright-line, calendar-day rule, not a window with soft edges. In a 2003 guidance, the agency stated it would determine 180-day exclusivity based on the calendar date of submission, not the hour or minute, because “CDER conducts its business by calendar day, not by the hour, minute, or second” [3]. That single sentence explains an entire industry behavior pattern described below. But the same guidance also shows how far companies will go to avoid ambiguity about which day counts, which is the opposite problem from the one this article addresses: a governance process too slow to notice the day matters at all.<\/p>\n\n\n\n

The Governance Mismatch: Quarterly Cycles Meeting a One-Day Deadline<\/strong><\/h2>\n\n\n\n

Public pharmaceutical companies disclose Paragraph IV litigation and exclusivity status primarily through SEC filings. Gilead’s 10-Q disclosed, quarter by quarter, the progress of Mylan’s Paragraph IV challenges to Tybost and Evotaz [5]. Amicus Therapeutics’ 10-K reported, on an annual and quarterly cadence, the ANDA challenges filed against Galafold by Aurobindo, Lupin, and Teva [6]. Warner Chilcott’s 10-Q tracked Watson’s and Lupin’s ANDA filings against Loestrin 24 Fe and Femcon Fe over a period of years [7]. This is not a criticism of these companies. It is a description of how corporate IP status routinely reaches decision-makers: through the same quarterly disclosure cycle that reports revenue and expenses.<\/p>\n\n\n\n

That cycle works well for information that changes slowly and needs periodic summarizing for investors. It works poorly for information that changes on one specific day and stays wrong forever if missed on that day. A quarterly review checks in roughly every 90 days. An NCE-1 date, a 45-day notice deadline, or a 30-month tentative-approval deadline does not wait for the next scheduled review. If the review happens to fall a week after the date has passed, the company has not caught up. It has confirmed a loss.<\/p>\n\n\n\n

The Camping-Outside-FDA Contrast<\/strong><\/h3>\n\n\n\n

The clearest illustration of how seriously the industry treats single-day precision, at the sharpest end of the spectrum, comes from a 2003 Federal Register account. FDA reported that a pharmaceutical company representative arrived outside an FDA-occupied building in mid-May 2003 to secure a place in line for ANDA submissions, one of which could not even be filed until mid-December that year. The company’s 24-hour presence for months went on until the building’s owner objected in a June 4, 2003 letter citing safety and liability concerns, at which point FDA had the waiting representative removed from the premises [3].<\/p>\n\n\n\n

That anecdote captures the two extremes of the same industry. Some companies treat a single calendar day as worth camping outside a federal building for. Others treat the same category of date as a line item that will surface, if at all, whenever legal counsel next prepares talking points for a 10-Q. Both behaviors respond to the same statute. Only one of them survives contact with a forfeiture provision.<\/p>\n\n\n\n

Case Study: Aubagio and the Twenty-One-Way Split<\/strong><\/h2>\n\n\n\n

Sanofi’s Aubagio (teriflunomide) was approved on September 12, 2012 under NDA 202992, setting the NCE-1 date at September 12, 2016 and full NCE expiry at September 12, 2017 [8]. Three Orange Book patents protected the product. Twenty-one separate ANDA applications, from different generic manufacturers, arrived at FDA on September 12, 2016, the NCE-1 date itself [8][9]. All twenty-one share whatever 180-day exclusivity is available, cutting the commercial value of first-filer status to roughly a twenty-first of what a sole filer would have captured.<\/p>\n\n\n\n

Sandoz tried a different approach entirely. On August 31, 2016, weeks before the NCE-1 date, Sandoz challenged FDA on whether Aubagio was even entitled to NCE status, arguing that FDA’s 1998 approval of Arava (leflunomide), which converts to teriflunomide in the body, amounted to a prior approval of teriflunomide as an active moiety. Sandoz then filed one ANDA on September 7, 2016, five days before the NCE-1 date and without a Paragraph IV certification, betting that if the NCE challenge succeeded, its early filing date would make it the sole first-filer. As a fallback, Sandoz also filed a second ANDA on September 12 with Paragraph IV certifications [9][10]. FDA rejected the NCE challenge. Sandoz sued, and in Sandoz Inc. v. Becerra the U.S. District Court for the District of Columbia ruled that FDA’s 1998 characterization of Arava’s entire formulation as the approved entity did not constitute approval of each metabolite within it. Teriflunomide remained a new active moiety, and Sandoz’s early ANDA never counted [10].<\/p>\n\n\n\n

The Aubagio episode shows what a governance process built for one specific date actually looks like in practice: a company preparing two separate filings, on two separate dates, weeks in advance, backed by litigation counsel ready to argue an active-moiety theory the moment the agency responded. That is not a quarterly review item. It is a standing operation.<\/p>\n\n\n\n

Case Study: Vascepa and the NCE-1 Date That Did Not Exist Yet<\/strong><\/h2>\n\n\n\n

Amarin’s Vascepa (icosapent ethyl) was approved July 26, 2012 under NDA 202057. On February 21, 2014, FDA denied Vascepa NCE exclusivity, reasoning that EPA, Vascepa’s active moiety, had already been present in Lovaza, a previously approved omega-3 mixture. Amarin sued, and on May 28, 2015, Judge Randolph D. Moss of the U.S. District Court for the District of Columbia vacated FDA’s determination, finding the agency had contradicted its own earlier characterization of Lovaza’s active ingredient as the entire mixture rather than any single component [11][12]. FDA did not issue a new determination until May 31, 2016, when it granted Vascepa five-year NCE exclusivity retroactive to the original July 26, 2012 approval date [12][13].<\/p>\n\n\n\n

That retroactive grant meant Vascepa’s NCE-1 date was itself only definitively known, after roughly two years of litigation, on the same day it was already passing: July 26, 2016. Generic companies preparing Paragraph IV ANDAs against Vascepa had to track ongoing FDA administrative proceedings and district court litigation for two years just to learn whether an NCE-1 date existed for this drug at all, and if so, when [12]. A company that treated Vascepa’s exclusivity status as a fixed fact, reviewed once a quarter and then filed away, would have carried a stale assumption through several review cycles while the actual determination moved through a federal courtroom.<\/p>\n\n\n\n

Case Study: Teva and the Thirty-Month Deadline That Became a Decade<\/strong><\/h2>\n\n\n\n

The NCE-1 date is not the only single-fixed-point deadline in this system. Once a first applicant files, it has 30 months from the filing date to obtain tentative FDA approval, or it risks forfeiting 180-day exclusivity entirely under 21 U.S.C. \u00a7 355(j)(5)(D)(i)(IV), unless the delay was caused by FDA’s own change in or review of approval requirements [14][15]. Teva’s ANDA for generic Cialis (tadalafil) shows how that fixed 30-month clock can run for years past its statutory endpoint before anyone forces a resolution.<\/p>\n\n\n\n

Teva filed the first Paragraph IV ANDA against Cialis on November 21, 2007 for the 5 mg, 10 mg, and 20 mg strengths, and on October 14, 2008 for the 2.5 mg strength, under a single ANDA, 090141 [16]. The 30-month forfeiture deadlines fell on May 21, 2010 and April 14, 2011 respectively. FDA issued chemistry deficiencies in October 2009. Teva submitted a chemistry amendment on April 15, 2010, roughly five weeks before the first deadline. FDA’s review of that amendment extended past May 21, 2010, and was not completed until October 15, 2010 [16]. Tentative approval did not arrive until March 10, 2017, roughly nine years and four months after the original filing. Final approval followed on May 22, 2018, one day after an unrelated period of pediatric exclusivity on the reference drug expired [16][17].<\/p>\n\n\n\n

Calculated interval, original to this analysis: from Teva’s November 21, 2007 filing to its March 10, 2017 tentative approval is approximately 112 months, or roughly 82 months past the original 30-month (900-day) statutory benchmark. FDA ultimately did not treat this as a forfeiture event, because the delay traced to FDA’s own extended chemistry review rather than any Teva inaction [16]. But the case demonstrates that a single statutory clock, “30 months,” can silently become a decade-long open question that nobody resolves until a tentative approval letter forces the issue.<\/p>\n\n\n\n

How Common Is Missing the Thirty-Month Window?<\/strong><\/h3>\n\n\n\n

Teva’s Cialis ANDA is not an isolated event. FDA’s own ANDA approval letters, publicly posted at accessdata.fda.gov, contain the same boilerplate finding across several unrelated Teva filings: for a generic naltrexone extended-release injectable (referencing Vivitrol), for tasimelteon capsules (referencing Hetlioz), for brexpiprazole tablets (referencing Rexulti), and for a mixed-salts amphetamine extended-release capsule, FDA’s approval letters each separately note that “Teva failed to obtain tentative approval of its ANDA within 30 months after the date on which the application was filed,” without FDA immediately determining whether forfeiture applies [18][19][20][21]. In a related 2012 case involving generic Exforge HCT (amlodipine, valsartan, and hydrochlorothiazide), Teva’s ANDA, filed around October 2009, was not tentatively approved until April 22, 2012 for four of five strengths, missing the 30-month mark; FDA excused the delay because it stemmed from FDA’s own mid-review change to tablet dissolution testing requirements [22].<\/p>\n\n\n\n

\n

“The most common [forfeiture trigger] is the applicant’s failure to receive tentative or final approval within 30 months after ANDA submission.” \u2014 Suchira Ghosh, counsel, Axinn, Veltrop & Harkrider LLP, quoted in BioPharm International [23]<\/p>\n<\/blockquote>\n\n\n\n

These are not small or under-resourced companies. Teva is one of the largest generic manufacturers in the world, with dedicated regulatory affairs and Paragraph IV litigation teams. The recurrence of the same 30-month boilerplate language across multiple, unrelated ANDAs shows that even sophisticated filers routinely cross this deadline. What changes the outcome is not whether the date gets missed. Dates get missed regularly, for reasons inside and outside a company’s control. What changes the outcome is whether anyone is positioned to notice, in real time, why it was missed, before FDA or a competing applicant forces a forfeiture determination.<\/p>\n\n\n\n

Case Study: Loestrin 24 Fe and the Ambiguity of “May Have Forfeited”<\/strong><\/h2>\n\n\n\n

Watson Pharmaceuticals was the first filer against Warner Chilcott’s Loestrin 24 Fe. In a 2012 SEC filing, Warner Chilcott stated plainly that it “believes Watson may have forfeited its ‘first filer’ status as a result of its failure to obtain approval by the FDA of its ANDA within the requisite period” [24]. That sentence, sitting inside a routine quarterly SEC disclosure, is a brand company publicly noting uncertainty about whether its own generic competitor still held exclusivity rights, based on a statutory deadline that had already come and gone.<\/p>\n\n\n\n

The Loestrin 24 Fe dispute later became the center of a large reverse-payment antitrust case. Watson agreed under a 2009 settlement not to enter the market before January 22, 2014 or the date another generic launched, whichever came first [25][26]. In 2020, Warner Chilcott’s parent, Allergan, along with Watson and Lupin, settled a consolidated antitrust action for a total of $183.5 million, following claims that the parties had structured agreements to delay generic entry [27][28]. Whatever the antitrust merits, the underlying regulatory fact pattern illustrates the same problem: a 30-month statutory forfeiture deadline that both companies had to interpret, years after the fact, from partial and contested information, rather than from a settled determination made in real time.<\/p>\n\n\n\n

What “Parking” Teaches About Multi-Year Deadline Management<\/strong><\/h2>\n\n\n\n

Congress built the 2003 Medicare Modernization Act (MMA) forfeiture provisions specifically because first filers were sitting on unused 180-day exclusivity indefinitely, blocking every other generic competitor without ever launching a product themselves, a practice regulators call “parking” [29][14]. The Provigil (modafinil) case shows how this plays out on a multi-year timeline that a quarterly cycle cannot supervise.<\/p>\n\n\n\n

Four generic companies, Teva, Ranbaxy, Mylan, and Barr, filed Paragraph IV ANDAs against modafinil on the same first day in 2002, earning shared first-filer status. Cephalon, the brand holder, sued all four in March 2003, triggering 30-month stays, and then settled with each of them on terms the FTC later alleged were structured specifically to avoid triggering the “court decision” event that would start the 180-day clock running [29][30]. The FTC sued Cephalon in February 2008, arguing the settlements amounted to a $200 million-plus reverse payment scheme to delay generic entry. By the time Teva acquired Cephalon and the exclusivity dispute reached the courts again in 2012, Mylan v. Sebelius determined that Teva alone, not the other three original first filers, held the exclusivity rights, and the FTC filed an amicus brief raising concerns about how that outcome had unfolded [30][31].<\/p>\n\n\n\n

The relevant point for governance purposes is the multi-year span. From the original same-day filing in 2002 to the FTC’s final 2012 statement on Teva’s acquisition of Cephalon and its effect on exclusivity, roughly a decade passed. A “we’ll catch it in the quarterly review” process implies roughly forty quarterly check-ins across that period. Forfeiture and parking questions of this kind are not resolved by showing up forty times. They are resolved by someone with standing authority tracking the specific triggering events (settlement terms, court filings, and marketing dates) continuously, because any one of those events can retroactively determine which of several companies actually holds a right that has already been worth hundreds of millions of dollars.<\/p>\n\n\n\n

An Original Taxonomy: Four Places Where Corporate Cadence Breaks a Filing Date<\/strong><\/h2>\n\n\n\n

The cases above point to a recurring pattern rather than isolated bad luck. This is an original framework, not an established industry term, built from the fact patterns documented above.<\/p>\n\n\n\n

1. The Periodic Legal Review Gap<\/strong><\/h3>\n\n\n\n

Patent and regulatory counsel review Orange Book status, ANDA filings, and exclusivity determinations on a fixed calendar cycle, often quarterly, aligned to board meetings or SEC reporting deadlines rather than to the specific dates that matter for any given drug. A date-triggered process would flag “NCE-1 date in 45 days” as an event. A periodic process notices it only when the review happens to fall near that date.<\/p>\n\n\n\n

2. Disclosure-as-Tracking Substitution<\/strong><\/h3>\n\n\n\n

Because Paragraph IV status appears in 10-Q and 10-K filings, the process of preparing those disclosures, which happens on a quarterly cadence by design, becomes the de facto moment a company’s own IP status gets reviewed with real scrutiny. The Gilead, Amicus, and Warner Chilcott examples above all show companies narrating exclusivity status inside routine quarterly filings [5][6][7][24]. That is appropriate for investor disclosure. It is a poor substitute for a system built to catch a single day.<\/p>\n\n\n\n

3. The Cross-Functional Handoff Gap<\/strong><\/h3>\n\n\n\n

A complete NCE-1 filing needs bioequivalence data, chemistry, manufacturing, and controls documentation, and a Paragraph IV legal certification, generally owned by three different functions inside a generic company: regulatory affairs, quality\/manufacturing, and IP litigation counsel. Each function may review its own piece on its own schedule. No one of them, on a quarterly cycle, is positioned to confirm that all three pieces converge on the same calendar day, which is precisely the “substantially complete” requirement FDA enforces at filing [4].<\/p>\n\n\n\n

4. Portfolio Dilution<\/strong><\/h3>\n\n\n\n

A company or law firm tracking dozens of Orange Book products at once tends to give each one roughly equal quarterly attention. But in any given quarter, only a handful of those products have a single-day-precision deadline actually falling inside that window. A review process calibrated to portfolio breadth, rather than to which specific dates fall due in the next 90 days, spends attention on a flat schedule instead of the sharp deadline calendar the statute actually creates.<\/p>\n\n\n\n

Comparing Four Documented Governance Failures<\/strong><\/h2>\n\n\n\n
Drug \/ Company<\/th>Deadline Type<\/th>What Happened<\/th>Outcome<\/th>Source<\/th><\/tr>
Aubagio \/ Sandoz<\/td>NCE-1 date, Sept. 12, 2016<\/td>Sandoz filed an early ANDA five days ahead of NCE-1, betting on an active-moiety challenge, plus a backup NCE-1-date filing<\/td>Challenge rejected by FDA and courts (Sandoz Inc. v. Becerra, 2022); Sandoz shared exclusivity with 20 other same-day filers<\/td>[9][10]<\/td><\/tr>
Vascepa \/ Amarin<\/td>NCE-1 date, contested 2014-2016<\/td>FDA denied, then (after litigation) retroactively granted, NCE exclusivity, fixing the NCE-1 date two years after the fact<\/td>NCE-1 date confirmed as July 26, 2016, only as it was already arriving<\/td>[11][12][13]<\/td><\/tr>
Cialis \/ Teva<\/td>30-month tentative approval deadline<\/td>FDA’s own extended chemistry review pushed tentative approval nine-plus years past filing<\/td>No forfeiture found; delay attributed to FDA-caused review changes<\/td>[16]<\/td><\/tr>
Loestrin 24 Fe \/ Watson<\/td>30-month tentative approval deadline<\/td>Brand company publicly stated in an SEC filing that Watson “may have forfeited” first-filer status<\/td>Resolved by settlement rather than a formal FDA forfeiture ruling; later became part of a $183.5 million antitrust settlement<\/td>[24][27]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Which Drugs Have an NCE-1 Date on the Calendar Right Now<\/strong><\/h2>\n\n\n\n

The four-year NCE-1 lag means today’s filing rush is always determined by approvals from four years earlier. Based on Orange Book and NCE tracking data, several 2022-era NCE approvals are reaching their NCE-1 dates in the 2026-2027 window: Sotyktu (deucravacitinib, Bristol Myers Squibb), approved September 9, 2022, with an NCE-1 date of September 9, 2026, and four Orange Book patents currently listed; Rezlidhia (olutasidenib, Rigel Pharmaceuticals), with an NCE-1 date in December 2026 and fourteen listed patents; Krazati (adagrasib, Bristol Myers Squibb); Sunlenca (lenacapavir sodium, Gilead Sciences), NCE-1 date in December 2026; and bexagliflozin, NCE-1 date in January 2027 [1]. Each of these represents a live instance of the same single-day filing race described in the Aubagio and Vascepa cases above, arriving on a schedule fixed years in advance and requiring the same real-time attention those cases show was often missing.<\/p>\n\n\n\n

Methodology<\/strong><\/h2>\n\n\n\n

This analysis draws on primary sources wherever available: 21 C.F.R. \u00a7 314.108 and the underlying FD&C Act provisions; the 2003 FDA guidance and Federal Register notice on same-day ANDA filings; the Sandoz v. Becerra district court opinion; FDA’s own ANDA approval letters posted at accessdata.fda.gov, which routinely note 30-month forfeiture-window findings in their boilerplate language; and SEC 10-K\/10-Q filings from Gilead, Amicus Therapeutics, Warner Chilcott, and Amarin describing their own companies’ or competitors’ Paragraph IV and exclusivity status over time. Secondary sources, including FDA Law Blog, BioPharm International, Faegre Drinker, and Lexology commentary, are used to provide legal context and are not the sole support for any factual claim where a primary source exists. Dates for NCE-1 and NCE-expiry calculations are derived directly from NDA approval dates using the four-year and five-year statutory formula; these derived dates are labeled as calculations, not as independently reported figures. Where FDA has not made a final forfeiture determination on the record, this article describes a company’s exclusivity as contested or at risk rather than as forfeited, since the statute reserves that formal determination for FDA itself, typically only once a competing applicant’s approval forces the question.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n